Nordic Bioscience A/S, headquartered in Denmark (DK), is a pioneering biotechnology company specialising in the development of innovative solutions for the healthcare industry. Founded in 2002, the company has established itself as a leader in biomarker research and diagnostics, focusing on areas such as fibrosis, osteoarthritis, and cardiovascular diseases. With a commitment to advancing personalised medicine, Nordic Bioscience offers unique products and services, including proprietary biomarker assays and clinical trial support. Their cutting-edge technologies are designed to enhance patient outcomes and streamline drug development processes. Recognised for its scientific excellence, Nordic Bioscience has achieved significant milestones, positioning itself as a trusted partner in the global biopharmaceutical landscape.
How does Nordic Bioscience A/S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Nordic Bioscience A/S's score of 26 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Nordic Bioscience A/S, headquartered in Denmark (DK), currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges. As a result, there is no information on their Scope 1, 2, or 3 emissions, nor any significant achievements in emissions reduction. Without specific data or commitments, it is unclear how Nordic Bioscience A/S is addressing climate change or contributing to sustainability efforts within the industry.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Nordic Bioscience A/S has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
